What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to formally report Abbott Laboratories' financial results for the first quarter of 2018. It includes a press release detailing these results and the financial condition of the company.

What are non-GAAP financial measures, and why does Abbott use them?

Non-GAAP financial measures are financial metrics that exclude certain items from GAAP (Generally Accepted Accounting Principles) figures. Abbott uses them to provide investors with a clearer perspective on the company's ongoing operational performance by excluding unusual or unpredictable items, such as costs related to acquisitions, restructuring, debt extinguishment, and gains from business sales.

What specific items are excluded in Abbott's non-GAAP reporting for Q1 2018?

For Q1 2018, Abbott's non-GAAP measures exclude items like expenses from acquisitions and restructuring, charges from cost reduction initiatives, a gain from the sale of the Medical Optics business, and costs associated with early debt extinguishment. Intangible amortization expense is also excluded.

What is the significance of the sale of the Medical Optics business mentioned?

The sale of the Medical Optics business resulted in a recognized gain, which is an item that Abbott has excluded from its non-GAAP earnings calculations. This allows for a better comparison of the ongoing business segments' performance.

ABT 8-K: Earnings & Results

Summary

Abbott Laboratories (ABT) filed an 8-K on April 18, 2018, to report its first-quarter 2018 financial results. The filing primarily serves to furnish the accompanying press release, which details the company's operational performance and financial condition. Investors should note that Abbott utilizes non-GAAP financial measures in its reporting, which exclude certain items such as acquisition and restructuring expenses, cost reduction initiatives, gains from business divestitures (specifically the Medical Optics business), and debt extinguishment costs. The company's management believes these non-GAAP measures offer enhanced visibility into ongoing business performance, aiding investors in evaluating operational results. However, investors are advised to consider these non-GAAP figures alongside, and not as a replacement for, their GAAP-compliant counterparts.

Key Highlights

1Abbott Laboratories announced its first-quarter 2018 financial results on April 18, 2018.
2The 8-K filing incorporates by reference a press release containing detailed financial information.
3Abbott presented non-GAAP financial measures alongside GAAP measures to provide a clearer view of ongoing operational performance.
4Non-GAAP adjustments include expenses related to acquisitions, restructuring, cost reductions, debt extinguishment, and a gain from the sale of the Medical Optics business.
5The company's management believes these non-GAAP measures are crucial for assessing internal performance and for investor evaluation.
6Investors are cautioned to consider non-GAAP measures in conjunction with, and not as a substitute for, GAAP financial statements.

ABBOTT LABORATORIES 8-K Report, Financial Results (Apr 18, 2018)

Summary

Key Highlights

Frequently Asked Questions